Modality
Multispecific
MOA
AuroraAi
Target
BET
Pathway
Ferroptosis
MesoBreast Ca
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
~Jan 2024
→ ~Apr 2025
Phase 3
Jul 2025
→ Mar 2026
Phase 3Current
NCT08526031
231 pts·Meso
2025-07→2026-03·Active
231 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-172w agoPh3 Readout· Meso
Trial Timeline
Q3Q42026
P3
Active
Catalysts
Ph3 Readout
2026-03-17 · 2w ago
Meso
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08526031 | Phase 3 | Meso | Active | 231 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |